Cure8 research brief
Why This Matters
Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret monitoring results and choose tests.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis who use fecal calprotectin for monitoring, gastroenterologists and IBD clinicians who order or interpret FC/FIT/CRP tests, and researchers studying biomarker performance.
Study Snapshot
What To Know
This observational study of 133 adults (both UC and CD) undergoing ileocolonoscopy measured FC on three different platforms (latex agglutination, fluoroenzyme immunoassay, chemiluminescent immunoassay), quantitative FIT, and serum CRP, then compared correlations and diagnostic performance against endoscopic scores and the Nancy histologic index.
The authors report very high correlation between the three FC platforms (Spearman r ≈ 0.95–0.96) and assessed ROC-based performance using predefined cutoffs; they also examined whether combining fecal biomarkers with CRP or FIT improved prediction of endoscopic or histologic activity.
This summary is based on the abstract provided in the Europe PMC record (preprint). The full study has not completed peer review.
Keep In Mind
This is a single-center observational preprint from Thailand with most participants in clinical remission; findings are based on the provided abstract and have not completed peer review. Test performance can vary by population, assay, and lab procedures.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.